Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypertension | 54 | 2020 | 899 | 7.600 |
Why?
|
Antihypertensive Agents | 36 | 2020 | 338 | 5.070 |
Why?
|
Dementia | 30 | 2020 | 233 | 5.010 |
Why?
|
Cognition | 40 | 2020 | 524 | 3.560 |
Why?
|
Blood Pressure | 29 | 2020 | 803 | 3.550 |
Why?
|
Aged | 168 | 2020 | 9462 | 2.940 |
Why?
|
Diabetes Mellitus, Type 2 | 38 | 2018 | 1374 | 2.730 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2020 | 462 | 2.700 |
Why?
|
Cognition Disorders | 23 | 2018 | 389 | 2.460 |
Why?
|
Brain | 30 | 2019 | 930 | 2.430 |
Why?
|
Blood Pressure Determination | 10 | 2019 | 94 | 2.400 |
Why?
|
Humans | 203 | 2020 | 29013 | 2.160 |
Why?
|
Aged, 80 and over | 85 | 2020 | 3712 | 1.890 |
Why?
|
Female | 164 | 2020 | 18114 | 1.870 |
Why?
|
Exercise | 10 | 2020 | 587 | 1.790 |
Why?
|
Male | 149 | 2020 | 17768 | 1.770 |
Why?
|
Mobility Limitation | 14 | 2020 | 187 | 1.770 |
Why?
|
Cardiovascular Diseases | 28 | 2019 | 1007 | 1.740 |
Why?
|
Magnetic Resonance Imaging | 34 | 2019 | 1218 | 1.740 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2019 | 126 | 1.670 |
Why?
|
Activities of Daily Living | 17 | 2019 | 237 | 1.610 |
Why?
|
Disabled Persons | 16 | 2018 | 83 | 1.580 |
Why?
|
Aspirin | 7 | 2020 | 61 | 1.440 |
Why?
|
Exercise Therapy | 9 | 2017 | 229 | 1.430 |
Why?
|
Geriatric Assessment | 19 | 2020 | 355 | 1.420 |
Why?
|
Hypercholesterolemia | 6 | 2017 | 59 | 1.370 |
Why?
|
Alzheimer Disease | 10 | 2020 | 312 | 1.340 |
Why?
|
Life Style | 11 | 2020 | 363 | 1.310 |
Why?
|
Aging | 20 | 2017 | 880 | 1.190 |
Why?
|
Geriatrics | 4 | 2017 | 94 | 1.120 |
Why?
|
Ginkgo biloba | 10 | 2017 | 19 | 1.110 |
Why?
|
Osteoarthritis, Knee | 8 | 2015 | 80 | 1.080 |
Why?
|
Risk Factors | 47 | 2020 | 3509 | 1.070 |
Why?
|
Pravastatin | 5 | 2017 | 12 | 1.070 |
Why?
|
Middle Aged | 80 | 2020 | 10805 | 1.020 |
Why?
|
Frail Elderly | 5 | 2016 | 65 | 0.980 |
Why?
|
Plant Extracts | 8 | 2019 | 60 | 0.900 |
Why?
|
Anticholesteremic Agents | 4 | 2013 | 36 | 0.880 |
Why?
|
American Heart Association | 7 | 2019 | 83 | 0.850 |
Why?
|
Patient Compliance | 7 | 2017 | 208 | 0.840 |
Why?
|
Neuropsychological Tests | 21 | 2019 | 378 | 0.840 |
Why?
|
United States | 32 | 2020 | 3604 | 0.830 |
Why?
|
Motor Activity | 7 | 2013 | 310 | 0.790 |
Why?
|
Accidental Falls | 5 | 2019 | 204 | 0.780 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 373 | 0.760 |
Why?
|
Cardiology | 5 | 2018 | 71 | 0.760 |
Why?
|
Treatment Outcome | 32 | 2020 | 3099 | 0.750 |
Why?
|
Advance Care Planning | 1 | 2019 | 10 | 0.730 |
Why?
|
Disease Management | 5 | 2017 | 114 | 0.720 |
Why?
|
Documentation | 1 | 2019 | 32 | 0.710 |
Why?
|
Health Status | 12 | 2016 | 368 | 0.700 |
Why?
|
Hypoglycemic Agents | 6 | 2016 | 175 | 0.700 |
Why?
|
Disability Evaluation | 14 | 2017 | 210 | 0.690 |
Why?
|
Food Services | 3 | 2015 | 18 | 0.670 |
Why?
|
Double-Blind Method | 19 | 2020 | 501 | 0.650 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 71 | 0.630 |
Why?
|
Retirement | 1 | 2017 | 11 | 0.630 |
Why?
|
Myocardial Infarction | 7 | 2016 | 412 | 0.630 |
Why?
|
Decision Making | 1 | 2019 | 180 | 0.620 |
Why?
|
Phytotherapy | 5 | 2008 | 38 | 0.610 |
Why?
|
Cross-Sectional Studies | 24 | 2020 | 1353 | 0.610 |
Why?
|
Diabetic Angiopathies | 8 | 2015 | 137 | 0.610 |
Why?
|
Single-Blind Method | 12 | 2017 | 165 | 0.610 |
Why?
|
Internal Medicine | 1 | 2017 | 44 | 0.590 |
Why?
|
Vitamins | 2 | 2015 | 58 | 0.590 |
Why?
|
Memory | 9 | 2019 | 187 | 0.590 |
Why?
|
African Americans | 13 | 2018 | 1373 | 0.590 |
Why?
|
Obesity | 10 | 2015 | 1062 | 0.580 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 8 | 2014 | 134 | 0.570 |
Why?
|
Chronic Disease | 5 | 2019 | 369 | 0.560 |
Why?
|
Cohort Studies | 24 | 2019 | 1674 | 0.550 |
Why?
|
Follow-Up Studies | 25 | 2020 | 2106 | 0.550 |
Why?
|
Depression | 8 | 2016 | 378 | 0.550 |
Why?
|
Education, Medical, Undergraduate | 2 | 2014 | 84 | 0.550 |
Why?
|
Homebound Persons | 1 | 2015 | 8 | 0.540 |
Why?
|
Cholecalciferol | 1 | 2015 | 21 | 0.540 |
Why?
|
Adult | 30 | 2020 | 8391 | 0.530 |
Why?
|
Body Mass Index | 13 | 2016 | 862 | 0.520 |
Why?
|
Walking | 11 | 2015 | 177 | 0.520 |
Why?
|
Dietary Supplements | 3 | 2015 | 170 | 0.520 |
Why?
|
Health Education | 6 | 2017 | 121 | 0.520 |
Why?
|
Hypotension | 1 | 2015 | 47 | 0.520 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2020 | 266 | 0.510 |
Why?
|
Hospitalization | 7 | 2019 | 417 | 0.500 |
Why?
|
Patient Readmission | 1 | 2015 | 105 | 0.500 |
Why?
|
Acute Coronary Syndrome | 1 | 2016 | 175 | 0.500 |
Why?
|
Lipids | 2 | 2014 | 208 | 0.490 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2018 | 82 | 0.480 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2020 | 173 | 0.480 |
Why?
|
Glucose Metabolism Disorders | 1 | 2013 | 3 | 0.480 |
Why?
|
Cerebrovascular Disorders | 2 | 2013 | 48 | 0.480 |
Why?
|
Chlorthalidone | 7 | 2017 | 13 | 0.470 |
Why?
|
Organ Size | 11 | 2019 | 196 | 0.470 |
Why?
|
Calcium Channel Blockers | 7 | 2014 | 49 | 0.470 |
Why?
|
Models, Educational | 1 | 2013 | 18 | 0.460 |
Why?
|
Internship and Residency | 1 | 2017 | 283 | 0.460 |
Why?
|
Diuretics | 5 | 2013 | 22 | 0.460 |
Why?
|
Health Promotion | 3 | 2015 | 220 | 0.460 |
Why?
|
Pilot Projects | 7 | 2017 | 469 | 0.450 |
Why?
|
Cause of Death | 6 | 2020 | 219 | 0.440 |
Why?
|
Prospective Studies | 17 | 2020 | 2010 | 0.440 |
Why?
|
Diabetes Mellitus | 4 | 2017 | 360 | 0.430 |
Why?
|
Heart Failure | 3 | 2016 | 567 | 0.430 |
Why?
|
Blood Glucose | 9 | 2016 | 465 | 0.420 |
Why?
|
Coronary Artery Disease | 4 | 2015 | 358 | 0.410 |
Why?
|
Age Factors | 17 | 2020 | 1105 | 0.400 |
Why?
|
Risk Assessment | 10 | 2020 | 1300 | 0.390 |
Why?
|
Longitudinal Studies | 15 | 2019 | 708 | 0.390 |
Why?
|
Health Services for the Aged | 3 | 2019 | 25 | 0.380 |
Why?
|
Health Status Indicators | 6 | 2020 | 67 | 0.380 |
Why?
|
Research Design | 8 | 2020 | 285 | 0.380 |
Why?
|
Incidence | 10 | 2019 | 1105 | 0.370 |
Why?
|
Australia | 7 | 2020 | 66 | 0.370 |
Why?
|
Diabetes Complications | 4 | 2018 | 171 | 0.370 |
Why?
|
Prevalence | 11 | 2020 | 892 | 0.360 |
Why?
|
Amlodipine | 6 | 2017 | 14 | 0.350 |
Why?
|
Lisinopril | 6 | 2017 | 28 | 0.350 |
Why?
|
Weight Loss | 6 | 2015 | 413 | 0.350 |
Why?
|
Life Expectancy | 2 | 1999 | 16 | 0.340 |
Why?
|
Muscle Strength | 3 | 2013 | 139 | 0.320 |
Why?
|
Advisory Committees | 2 | 2017 | 32 | 0.310 |
Why?
|
Personal Satisfaction | 2 | 2008 | 25 | 0.310 |
Why?
|
Chondroitin | 1 | 2007 | 2 | 0.310 |
Why?
|
Glucosamine | 1 | 2007 | 7 | 0.310 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2007 | 16 | 0.310 |
Why?
|
Mortality | 3 | 2018 | 108 | 0.310 |
Why?
|
Diet, Reducing | 3 | 2015 | 90 | 0.300 |
Why?
|
Patient Care Planning | 2 | 2020 | 53 | 0.300 |
Why?
|
European Continental Ancestry Group | 7 | 2018 | 1131 | 0.290 |
Why?
|
Vascular Diseases | 3 | 2015 | 61 | 0.290 |
Why?
|
Deglutition | 3 | 2011 | 28 | 0.290 |
Why?
|
Executive Function | 2 | 2017 | 54 | 0.290 |
Why?
|
Respiratory Aspiration | 3 | 2011 | 21 | 0.290 |
Why?
|
Comorbidity | 10 | 2018 | 539 | 0.270 |
Why?
|
Anxiety | 4 | 2015 | 159 | 0.270 |
Why?
|
Albuminuria | 5 | 2020 | 174 | 0.260 |
Why?
|
Anxiety Disorders | 3 | 2012 | 60 | 0.260 |
Why?
|
Amyloid | 2 | 2017 | 17 | 0.260 |
Why?
|
Glomerular Filtration Rate | 8 | 2020 | 286 | 0.260 |
Why?
|
Homes for the Aged | 2 | 2003 | 18 | 0.260 |
Why?
|
Hypoglycemia | 3 | 2014 | 41 | 0.260 |
Why?
|
Carbamates | 1 | 2004 | 14 | 0.250 |
Why?
|
Nursing Homes | 2 | 2003 | 41 | 0.250 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 706 | 0.250 |
Why?
|
Metformin | 1 | 2004 | 19 | 0.250 |
Why?
|
Medication Adherence | 2 | 2016 | 144 | 0.250 |
Why?
|
Administration, Oral | 6 | 2018 | 169 | 0.250 |
Why?
|
Analysis of Variance | 6 | 2013 | 454 | 0.250 |
Why?
|
Patient Selection | 5 | 2020 | 257 | 0.250 |
Why?
|
Multicenter Studies as Topic | 3 | 2020 | 92 | 0.250 |
Why?
|
Severity of Illness Index | 11 | 2017 | 863 | 0.250 |
Why?
|
Independent Living | 4 | 2018 | 77 | 0.240 |
Why?
|
Diabetic Nephropathies | 3 | 2015 | 195 | 0.240 |
Why?
|
Clinical Competence | 3 | 2017 | 307 | 0.240 |
Why?
|
Genome-Wide Association Study | 3 | 2016 | 542 | 0.240 |
Why?
|
Hemorrhage | 3 | 2018 | 90 | 0.240 |
Why?
|
Community Health Services | 2 | 2020 | 54 | 0.240 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2013 | 18 | 0.240 |
Why?
|
Hip Fractures | 3 | 2017 | 30 | 0.240 |
Why?
|
Piperidines | 1 | 2004 | 125 | 0.230 |
Why?
|
Institutionalization | 1 | 2003 | 2 | 0.230 |
Why?
|
Overweight | 3 | 2014 | 256 | 0.230 |
Why?
|
Linear Models | 9 | 2017 | 425 | 0.230 |
Why?
|
Polymorphism, Genetic | 1 | 2014 | 196 | 0.220 |
Why?
|
Biostatistics | 1 | 2012 | 8 | 0.220 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2014 | 142 | 0.220 |
Why?
|
Time Factors | 11 | 2020 | 1997 | 0.220 |
Why?
|
Sexual Behavior | 1 | 2003 | 97 | 0.220 |
Why?
|
Goals | 2 | 2020 | 36 | 0.220 |
Why?
|
Death | 3 | 2017 | 41 | 0.220 |
Why?
|
Apolipoprotein E4 | 3 | 2019 | 58 | 0.220 |
Why?
|
Patient Transfer | 2 | 2020 | 34 | 0.220 |
Why?
|
Quality-Adjusted Life Years | 2 | 1999 | 23 | 0.220 |
Why?
|
Vitamin D | 2 | 2015 | 170 | 0.220 |
Why?
|
Antidepressive Agents | 3 | 2015 | 70 | 0.220 |
Why?
|
Medicare | 2 | 2019 | 185 | 0.210 |
Why?
|
Risk | 7 | 2020 | 289 | 0.210 |
Why?
|
Electronic Health Records | 2 | 2020 | 118 | 0.210 |
Why?
|
Disease-Free Survival | 2 | 2020 | 281 | 0.210 |
Why?
|
Sertraline | 2 | 2015 | 27 | 0.200 |
Why?
|
Health Surveys | 4 | 2019 | 191 | 0.200 |
Why?
|
Gait | 3 | 2014 | 115 | 0.200 |
Why?
|
Psychomotor Performance | 3 | 2011 | 97 | 0.200 |
Why?
|
Primary Health Care | 2 | 2017 | 178 | 0.200 |
Why?
|
Laryngoscopy | 2 | 2011 | 39 | 0.200 |
Why?
|
Quality of Life | 8 | 2020 | 815 | 0.200 |
Why?
|
Nerve Fibers, Myelinated | 2 | 2012 | 31 | 0.200 |
Why?
|
Depressive Disorder | 2 | 2015 | 74 | 0.200 |
Why?
|
Comprehensive Health Care | 1 | 2020 | 5 | 0.190 |
Why?
|
Women's Health | 3 | 2014 | 226 | 0.190 |
Why?
|
Prognosis | 9 | 2019 | 1362 | 0.190 |
Why?
|
Ideal Body Weight | 1 | 2009 | 7 | 0.180 |
Why?
|
Terminal Care | 1 | 2019 | 18 | 0.180 |
Why?
|
Staff Development | 1 | 2019 | 13 | 0.180 |
Why?
|
Awareness | 1 | 2019 | 28 | 0.180 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 298 | 0.180 |
Why?
|
Intelligence Tests | 3 | 2017 | 9 | 0.180 |
Why?
|
Teaching | 1 | 2019 | 55 | 0.180 |
Why?
|
Palliative Care | 1 | 2019 | 47 | 0.170 |
Why?
|
Patient Participation | 1 | 2019 | 62 | 0.170 |
Why?
|
Education, Medical | 1 | 2019 | 67 | 0.170 |
Why?
|
Hospital Mortality | 1 | 2020 | 186 | 0.170 |
Why?
|
Faculty, Medical | 1 | 2019 | 69 | 0.170 |
Why?
|
Artificial Intelligence | 2 | 2013 | 49 | 0.170 |
Why?
|
Creatinine | 5 | 2020 | 173 | 0.170 |
Why?
|
Physical Fitness | 3 | 2012 | 119 | 0.170 |
Why?
|
Cost-Benefit Analysis | 3 | 2020 | 159 | 0.170 |
Why?
|
Coronary Disease | 4 | 2013 | 197 | 0.170 |
Why?
|
Deglutition Disorders | 4 | 2011 | 50 | 0.170 |
Why?
|
Caregivers | 1 | 2019 | 94 | 0.160 |
Why?
|
North Carolina | 4 | 2020 | 1422 | 0.160 |
Why?
|
Genetic Association Studies | 2 | 2016 | 148 | 0.160 |
Why?
|
Syncope | 1 | 2018 | 24 | 0.160 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 154 | 0.150 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2017 | 13 | 0.150 |
Why?
|
Aniline Compounds | 2 | 2017 | 25 | 0.150 |
Why?
|
Fibrinolytic Agents | 1 | 2017 | 70 | 0.150 |
Why?
|
Feasibility Studies | 2 | 2015 | 262 | 0.150 |
Why?
|
Thiazoles | 2 | 2017 | 32 | 0.150 |
Why?
|
Gait Disorders, Neurologic | 1 | 2017 | 12 | 0.150 |
Why?
|
Early Termination of Clinical Trials | 1 | 2016 | 3 | 0.150 |
Why?
|
Hypotension, Orthostatic | 1 | 2016 | 10 | 0.150 |
Why?
|
Hand Strength | 2 | 2011 | 85 | 0.150 |
Why?
|
Logistic Models | 7 | 2013 | 725 | 0.150 |
Why?
|
Pelvic Bones | 1 | 2017 | 31 | 0.150 |
Why?
|
Alcohol Drinking | 1 | 2019 | 243 | 0.150 |
Why?
|
Comparative Effectiveness Research | 1 | 2016 | 23 | 0.150 |
Why?
|
Radiography | 4 | 2015 | 353 | 0.150 |
Why?
|
Genotype | 4 | 2017 | 735 | 0.150 |
Why?
|
Appointments and Schedules | 1 | 2016 | 16 | 0.140 |
Why?
|
Memory, Short-Term | 1 | 2017 | 59 | 0.140 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 64 | 0.140 |
Why?
|
Resistance Training | 2 | 2015 | 70 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 325 | 0.140 |
Why?
|
Aromatic-L-Amino-Acid Decarboxylases | 1 | 2016 | 4 | 0.140 |
Why?
|
Apolipoproteins E | 1 | 2016 | 97 | 0.140 |
Why?
|
Curriculum | 2 | 2019 | 196 | 0.140 |
Why?
|
Educational Measurement | 2 | 2014 | 111 | 0.140 |
Why?
|
Positron-Emission Tomography | 2 | 2017 | 172 | 0.140 |
Why?
|
Sex Factors | 4 | 2019 | 626 | 0.140 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2014 | 125 | 0.140 |
Why?
|
Thiazolidinediones | 1 | 2015 | 47 | 0.130 |
Why?
|
Physicians | 1 | 2017 | 134 | 0.130 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2015 | 35 | 0.130 |
Why?
|
Estrogen Replacement Therapy | 2 | 2014 | 182 | 0.130 |
Why?
|
Spectrin | 1 | 2014 | 5 | 0.130 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2014 | 12 | 0.130 |
Why?
|
Adiposity | 1 | 2016 | 191 | 0.130 |
Why?
|
Hippocampus | 1 | 2016 | 185 | 0.130 |
Why?
|
Body Composition | 3 | 2012 | 365 | 0.130 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2014 | 53 | 0.130 |
Why?
|
Algorithms | 4 | 2019 | 461 | 0.130 |
Why?
|
Motor Skills Disorders | 1 | 2014 | 4 | 0.130 |
Why?
|
Brain Diseases | 1 | 2014 | 40 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2016 | 196 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 2 | 2014 | 836 | 0.120 |
Why?
|
Treatment Failure | 3 | 2018 | 159 | 0.120 |
Why?
|
Diabetic Retinopathy | 1 | 2014 | 64 | 0.120 |
Why?
|
Tablets, Enteric-Coated | 1 | 2013 | 1 | 0.120 |
Why?
|
Exercise Test | 4 | 2017 | 194 | 0.120 |
Why?
|
Atrophy | 4 | 2015 | 51 | 0.120 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 247 | 0.120 |
Why?
|
Pneumonia | 1 | 2014 | 61 | 0.120 |
Why?
|
Disease Progression | 4 | 2015 | 572 | 0.120 |
Why?
|
Biological Transport | 1 | 2013 | 62 | 0.120 |
Why?
|
Fractures, Bone | 1 | 2015 | 149 | 0.120 |
Why?
|
Stroke | 2 | 2017 | 522 | 0.120 |
Why?
|
Kidney Diseases | 1 | 2016 | 239 | 0.120 |
Why?
|
Dopamine | 1 | 2016 | 226 | 0.110 |
Why?
|
Amyloidosis | 1 | 2013 | 10 | 0.110 |
Why?
|
Kidney Failure, Chronic | 2 | 2014 | 518 | 0.110 |
Why?
|
Odds Ratio | 4 | 2010 | 446 | 0.110 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 46 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2014 | 241 | 0.110 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 87 | 0.110 |
Why?
|
Telephone | 1 | 2012 | 48 | 0.110 |
Why?
|
Signal Transduction | 1 | 2016 | 666 | 0.110 |
Why?
|
Regression Analysis | 3 | 2016 | 272 | 0.110 |
Why?
|
Psychiatric Status Rating Scales | 4 | 2015 | 92 | 0.110 |
Why?
|
Cholesterol | 1 | 2013 | 229 | 0.110 |
Why?
|
Gastrointestinal Transit | 1 | 2011 | 4 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2015 | 524 | 0.110 |
Why?
|
Vitamin D Deficiency | 1 | 2012 | 89 | 0.100 |
Why?
|
Kidney Function Tests | 3 | 2017 | 102 | 0.100 |
Why?
|
Survival Analysis | 3 | 2019 | 440 | 0.100 |
Why?
|
Neoplasms | 2 | 2018 | 608 | 0.100 |
Why?
|
Leg | 2 | 2004 | 56 | 0.100 |
Why?
|
Smoking | 3 | 2017 | 427 | 0.100 |
Why?
|
Tongue | 1 | 2011 | 13 | 0.100 |
Why?
|
Nootropic Agents | 1 | 2011 | 13 | 0.100 |
Why?
|
Pain Measurement | 4 | 2013 | 360 | 0.100 |
Why?
|
Esophageal Sphincter, Upper | 1 | 2010 | 3 | 0.100 |
Why?
|
Pharynx | 1 | 2010 | 10 | 0.100 |
Why?
|
Doxazosin | 1 | 2000 | 6 | 0.090 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2000 | 27 | 0.090 |
Why?
|
Hypertensive Encephalopathy | 1 | 2010 | 1 | 0.090 |
Why?
|
Mental Status Schedule | 4 | 2017 | 24 | 0.090 |
Why?
|
Drug Therapy, Combination | 3 | 2010 | 273 | 0.090 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 385 | 0.090 |
Why?
|
Forecasting | 2 | 2003 | 133 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2013 | 420 | 0.090 |
Why?
|
Reference Values | 4 | 2013 | 224 | 0.090 |
Why?
|
Sample Size | 2 | 2020 | 37 | 0.090 |
Why?
|
Atherosclerosis | 1 | 2015 | 691 | 0.090 |
Why?
|
Osteoarthritis | 2 | 2003 | 74 | 0.090 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2009 | 48 | 0.090 |
Why?
|
Consensus | 2 | 2018 | 68 | 0.080 |
Why?
|
Cerebral Cortex | 1 | 2009 | 141 | 0.080 |
Why?
|
Pain | 2 | 2009 | 282 | 0.080 |
Why?
|
Knee Joint | 1 | 2009 | 129 | 0.080 |
Why?
|
Erythrocytes | 1 | 2008 | 43 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2017 | 636 | 0.080 |
Why?
|
Pennsylvania | 3 | 2012 | 77 | 0.080 |
Why?
|
Retrospective Studies | 5 | 2020 | 3107 | 0.080 |
Why?
|
Primary Prevention | 2 | 2017 | 47 | 0.080 |
Why?
|
Kidney | 1 | 2011 | 485 | 0.080 |
Why?
|
Evidence-Based Medicine | 2 | 2018 | 207 | 0.070 |
Why?
|
Oxygen | 1 | 2008 | 139 | 0.070 |
Why?
|
Survival Rate | 2 | 2020 | 795 | 0.070 |
Why?
|
Plant Preparations | 1 | 2006 | 21 | 0.070 |
Why?
|
Cholesterol, LDL | 2 | 2017 | 156 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2016 | 1079 | 0.070 |
Why?
|
Mental Recall | 1 | 2006 | 52 | 0.070 |
Why?
|
Adipose Tissue | 3 | 2016 | 327 | 0.070 |
Why?
|
Hyperparathyroidism | 1 | 2005 | 7 | 0.070 |
Why?
|
Parathyroidectomy | 1 | 2005 | 10 | 0.070 |
Why?
|
Hemoglobins | 1 | 2005 | 42 | 0.070 |
Why?
|
Health Behavior | 2 | 2006 | 212 | 0.070 |
Why?
|
Muscle Weakness | 2 | 2011 | 39 | 0.070 |
Why?
|
Intention to Treat Analysis | 2 | 2017 | 23 | 0.060 |
Why?
|
Brachial Artery | 1 | 2004 | 66 | 0.060 |
Why?
|
Confidence Intervals | 3 | 2017 | 140 | 0.060 |
Why?
|
Vasodilation | 1 | 2004 | 87 | 0.060 |
Why?
|
Sickness Impact Profile | 1 | 2004 | 34 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2013 | 784 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2005 | 126 | 0.060 |
Why?
|
Gene Frequency | 1 | 2014 | 225 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2011 | 724 | 0.060 |
Why?
|
Pedigree | 2 | 2016 | 133 | 0.060 |
Why?
|
African Continental Ancestry Group | 2 | 2016 | 350 | 0.060 |
Why?
|
Albumins | 2 | 2014 | 38 | 0.060 |
Why?
|
Marriage | 1 | 2003 | 4 | 0.060 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 66 | 0.060 |
Why?
|
Long-Term Care | 1 | 2003 | 21 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2014 | 59 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2012 | 19 | 0.060 |
Why?
|
Systole | 3 | 2014 | 87 | 0.060 |
Why?
|
Principal Component Analysis | 1 | 2012 | 60 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2003 | 88 | 0.050 |
Why?
|
Demography | 2 | 2016 | 104 | 0.050 |
Why?
|
Probability | 2 | 2004 | 150 | 0.050 |
Why?
|
Tennessee | 2 | 2012 | 97 | 0.050 |
Why?
|
Reserpine | 1 | 2001 | 3 | 0.050 |
Why?
|
Atenolol | 1 | 2001 | 6 | 0.050 |
Why?
|
Muscles | 1 | 2002 | 53 | 0.050 |
Why?
|
Weight-Bearing | 2 | 2013 | 40 | 0.050 |
Why?
|
Laryngoscopes | 2 | 2011 | 12 | 0.050 |
Why?
|
Sex Distribution | 2 | 2017 | 185 | 0.050 |
Why?
|
Databases, Factual | 1 | 2012 | 331 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 292 | 0.050 |
Why?
|
Diet | 1 | 2003 | 348 | 0.050 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 26 | 0.050 |
Why?
|
Polypharmacy | 1 | 2020 | 20 | 0.050 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 49 | 0.050 |
Why?
|
Captopril | 1 | 2000 | 8 | 0.050 |
Why?
|
Risk Adjustment | 1 | 2020 | 27 | 0.050 |
Why?
|
Nutritional Status | 1 | 2001 | 68 | 0.050 |
Why?
|
Sodium Chloride Symporter Inhibitors | 2 | 2014 | 10 | 0.050 |
Why?
|
Food Supply | 1 | 2001 | 52 | 0.050 |
Why?
|
Poverty | 1 | 2001 | 98 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 641 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2009 | 26 | 0.050 |
Why?
|
Drinking Behavior | 1 | 2019 | 10 | 0.050 |
Why?
|
Muscle, Skeletal | 1 | 2004 | 494 | 0.040 |
Why?
|
Video Recording | 1 | 2019 | 51 | 0.040 |
Why?
|
Angina Pectoris | 1 | 1999 | 19 | 0.040 |
Why?
|
Program Development | 1 | 2019 | 85 | 0.040 |
Why?
|
Random Allocation | 2 | 2015 | 212 | 0.040 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 25 | 0.040 |
Why?
|
Life Tables | 1 | 1998 | 4 | 0.040 |
Why?
|
Verbal Behavior | 1 | 1998 | 9 | 0.040 |
Why?
|
Judgment | 1 | 1998 | 11 | 0.040 |
Why?
|
Body Height | 1 | 1998 | 30 | 0.040 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2017 | 39 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2017 | 12 | 0.040 |
Why?
|
Mass Screening | 1 | 2019 | 223 | 0.040 |
Why?
|
Drug Monitoring | 1 | 2017 | 24 | 0.040 |
Why?
|
Biomedical Research | 1 | 2019 | 153 | 0.040 |
Why?
|
Statistics as Topic | 1 | 2017 | 106 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2019 | 142 | 0.040 |
Why?
|
Age Distribution | 1 | 2017 | 197 | 0.040 |
Why?
|
Carbon Radioisotopes | 1 | 2017 | 20 | 0.040 |
Why?
|
Visual Perception | 1 | 1998 | 112 | 0.040 |
Why?
|
Heterozygote | 1 | 2016 | 52 | 0.040 |
Why?
|
North America | 1 | 2016 | 33 | 0.040 |
Why?
|
Epidemiologic Studies | 2 | 2010 | 20 | 0.040 |
Why?
|
Waist Circumference | 1 | 2016 | 88 | 0.040 |
Why?
|
Minisatellite Repeats | 1 | 2016 | 8 | 0.040 |
Why?
|
Hyperglycemia | 1 | 2016 | 82 | 0.040 |
Why?
|
Physical Examination | 1 | 2016 | 82 | 0.040 |
Why?
|
Body Weight | 1 | 1998 | 290 | 0.030 |
Why?
|
Muscle Stretching Exercises | 1 | 2015 | 4 | 0.030 |
Why?
|
Mental Health | 1 | 2016 | 102 | 0.030 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 2015 | 17 | 0.030 |
Why?
|
Postural Balance | 1 | 2017 | 160 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2015 | 64 | 0.030 |
Why?
|
Patient Discharge | 1 | 2016 | 168 | 0.030 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 2016 | 96 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 2015 | 95 | 0.030 |
Why?
|
Upper Extremity | 1 | 2015 | 52 | 0.030 |
Why?
|
Stroop Test | 1 | 2014 | 5 | 0.030 |
Why?
|
Survivors | 1 | 2016 | 145 | 0.030 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.030 |
Why?
|
Propensity Score | 1 | 2014 | 34 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2014 | 95 | 0.030 |
Why?
|
Receptor, EphA1 | 1 | 2013 | 2 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2015 | 389 | 0.030 |
Why?
|
Heart Diseases | 1 | 2014 | 97 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2008 | 855 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2015 | 264 | 0.030 |
Why?
|
Educational Status | 1 | 2014 | 162 | 0.030 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2013 | 60 | 0.030 |
Why?
|
Brain Mapping | 1 | 2014 | 182 | 0.030 |
Why?
|
Models, Neurological | 1 | 2014 | 115 | 0.030 |
Why?
|
Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
Homeostasis | 1 | 2013 | 127 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2014 | 113 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2013 | 59 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 629 | 0.030 |
Why?
|
Nerve Net | 1 | 2014 | 115 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2013 | 128 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2013 | 224 | 0.030 |
Why?
|
Age of Onset | 1 | 2012 | 95 | 0.030 |
Why?
|
Parathyroid Hormone | 1 | 2012 | 38 | 0.030 |
Why?
|
Urban Population | 1 | 2012 | 79 | 0.030 |
Why?
|
Esophageal Motility Disorders | 1 | 2011 | 6 | 0.030 |
Why?
|
Viscosity | 1 | 2011 | 21 | 0.030 |
Why?
|
Nursing Assessment | 1 | 2011 | 11 | 0.030 |
Why?
|
Food | 1 | 2011 | 41 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 871 | 0.030 |
Why?
|
Cystatin C | 1 | 2011 | 28 | 0.030 |
Why?
|
Cost of Illness | 1 | 2011 | 63 | 0.020 |
Why?
|
Animals | 2 | 2015 | 7297 | 0.020 |
Why?
|
Milk | 1 | 2010 | 11 | 0.020 |
Why?
|
Pressure | 1 | 2010 | 54 | 0.020 |
Why?
|
Water | 1 | 2010 | 50 | 0.020 |
Why?
|
Mathematics | 1 | 2010 | 9 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2012 | 251 | 0.020 |
Why?
|
Equipment Design | 1 | 2010 | 167 | 0.020 |
Why?
|
Inflammation | 1 | 2013 | 503 | 0.020 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2010 | 89 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2009 | 42 | 0.020 |
Why?
|
Psychological Tests | 1 | 2009 | 33 | 0.020 |
Why?
|
Adolescent | 2 | 2007 | 3248 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2009 | 101 | 0.020 |
Why?
|
Length of Stay | 2 | 2003 | 291 | 0.020 |
Why?
|
Recovery of Function | 1 | 2009 | 190 | 0.020 |
Why?
|
Ethnic Groups | 1 | 2010 | 440 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2008 | 70 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 531 | 0.020 |
Why?
|
Self Efficacy | 1 | 2008 | 70 | 0.020 |
Why?
|
Young Adult | 1 | 2014 | 2398 | 0.020 |
Why?
|
Canada | 1 | 2007 | 48 | 0.020 |
Why?
|
Sampling Studies | 1 | 2006 | 40 | 0.020 |
Why?
|
Dementia, Vascular | 1 | 2006 | 13 | 0.020 |
Why?
|
Postoperative Period | 1 | 2005 | 91 | 0.020 |
Why?
|
Psychotropic Drugs | 1 | 2005 | 10 | 0.020 |
Why?
|
Anti-Anxiety Agents | 1 | 2005 | 13 | 0.020 |
Why?
|
Psychology | 1 | 2005 | 22 | 0.020 |
Why?
|
Preoperative Care | 1 | 2005 | 110 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2005 | 125 | 0.020 |
Why?
|
Emotions | 1 | 2005 | 48 | 0.020 |
Why?
|
Benzothiadiazines | 1 | 2004 | 2 | 0.020 |
Why?
|
Italy | 1 | 2003 | 15 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2003 | 139 | 0.010 |
Why?
|
Muscular Atrophy | 1 | 2002 | 67 | 0.010 |
Why?
|
Nutrition Disorders | 1 | 2001 | 12 | 0.010 |
Why?
|
Baltimore | 1 | 2001 | 49 | 0.010 |
Why?
|
Diastole | 1 | 2000 | 90 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 1999 | 4 | 0.010 |
Why?
|
Patient Dropouts | 1 | 1999 | 24 | 0.010 |
Why?
|
Models, Statistical | 1 | 1999 | 160 | 0.010 |
Why?
|
Isometric Contraction | 1 | 1998 | 21 | 0.010 |
Why?
|
Torque | 1 | 1998 | 19 | 0.010 |
Why?
|
Maryland | 1 | 1998 | 26 | 0.010 |
Why?
|
Social Perception | 1 | 1998 | 21 | 0.010 |
Why?
|
Range of Motion, Articular | 1 | 1998 | 177 | 0.010 |
Why?
|
Morbidity | 1 | 1996 | 91 | 0.010 |
Why?
|